leadf
logo-loader
viewBioVaxys Technology Corp.
(
CSE:BIOVOTCQB:BVAXF
)

BioVaxys's partner completes synthesis of recombinant SARS-CoV-2 s-protein for its two programs

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF)'s Kenneth Kovan and Yvelise Barrios joined Proactive to discuss how its global CDMO partner WuXi Biologics has completed the synthesis of recombinant SARS-CoV-2 s-protein for the BVX-0320 and CoviDTH programs.

BVX-0320 is BioVaxys’ COVID-19 vaccine candidate and CoviDTH its immunodiagnostic product. Both are headed for clinical trials, with BioVaxys having begun preparing an Investigational New Drug submission to the US Food and Drug Administration for a combined Phase I/II clinical study of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.

Quick facts: BioVaxys Technology Corp.

Follow
CSE:BIOV

Price: 0.55 CAD

Market Cap: $44.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

BioVaxys preps for Phase 1 study as vaccine manufacturing partner reaches...

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) COO Kenneth Kovan tells Proactive that cancer vaccine manufacturing partner Bio Elpida has reached major milestones in the development of the bioproduction process for BVX-0918A, BioVaxys’ ovarian cancer vaccine. Kovan says the Lyon,...

4 days, 7 hours ago

2 min read